Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035848 | 0.94 | ALDH1A1 (0.38) | ALDH1A1TNKS2ESR1APOBEC3AAPOBEC3G | |
| SCHEMBL1037184 | 0.81 | LMNA (0.38) | ALDH1A1KDM4ELMNA | |
| SCHEMBL12956843 | 0.80 | HPGD (0.37) | ESR1PTGS2KDM4ELMNATHRA | |
| SCHEMBL691938 | 0.75 | HPGD (0.34) | ALDH1A1KDM4ELMNA | |
| SCHEMBL1033190 | 0.75 | NAAA (0.45) | ALDH1A1ESR1LMNACNR1CNR2 | |
| SCHEMBL16401942 | 0.75 | NAAA (0.45) | ALDH1A1ESR1LMNACNR1CNR2 | |
| SCHEMBL1037395 | 0.73 | PTGS2 (0.36) | ALDH1A1TNKS2ESR1PTGS2APOBEC3A | |
| SCHEMBL12956434 | 0.72 | LMNA (0.40) | ALDH1A1KDM4ELMNA | |
| SCHEMBL2711699 | 0.70 | GAA (0.32) | ALDH1A1LMNATDP1 | |
| SCHEMBL15637145 | 0.70 | ALDH1A1 (0.31) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814891-B1 | BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES | BASF SE (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1814891-B1 | BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES | BASF SE (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7687657-B2 | Process for preparing acylphosphanes and derivatives thereof | CIBA SPECIALITY CHEMICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687657-B2 | Process for preparing acylphosphanes and derivatives thereof | CIBA SPECIALITY CHEMICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687657-B2 | Process for preparing acylphosphanes and derivatives thereof | CIBA SPECIALITY CHEMICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | IGM GROUP B.V. (NL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | IGM GROUP B.V. (NL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | IGM GROUP B.V. (NL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004464-A1 | Process for Preparing Acylphosphanes and Derivatives Thereof | ME2, ME3, MEP1A | ALDH1A1 248/4885TNKS2 1526/4885ESR1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.